Genetics of Hypertension

高血压的遗传学

基本信息

  • 批准号:
    8392241
  • 负责人:
  • 金额:
    $ 35.65万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2011
  • 资助国家:
    美国
  • 起止时间:
    2011-07-15 至 2014-11-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Hypertension is a serious risk factor for myocardial infarction, heart failure, vascular disease, stroke, and renal failure. Angiotensinogen (AGT) gene locus is associated with human essential hypertension and its expression is increased by glucocorticoid and IL-6 treatment. Previous studies have shown that variant -6A of the AGT gene is associated with increased plasma AGT level and increased blood pressure in Caucasian and Japanese population. However, transgenic mice containing 1.2 Kb of the promoter with -6A allele of the hAGT gene neither show increased transcription nor increased blood pressure compared to transgenic mice containing -6G allele. We have found that hAGT gene has three additional SNPs (A/G at -1670, C/G at -1562 and T/G at -1561) and variants -1670A, - 1562C, and -1561T almost always occur with variant -6A. Therefore hAGT gene may be subdivided in either -6A haplotype (containing -6A, -1561T, -1562C, -1670A) or -6G haplotype (containing -6G, -1561G, -15652, -1670G). Our transient transfection assays show that reporter construct with -6A haplotype has four fold increased glucocorticoid and five fold increased IL-6 induced promoter activity as compared to the reporter construct with -6G haplotype in liver and kidney cells. In order to understand the role of glucocorticoids and IL-6 on transcription of -6A and -6G haplotypes of the hAGT gene and on the regulation of blood pressure in an in vivo situation, we have re-combineered 180 Kb long BAC DNA (containing 116 Kb of the 5'-flanking region, all five exons and four introns, and 54 Kb of the 3'-UTR of the hAGT gene) and produced double transgenic mice containing either -6A or - 6G haplotype of the hAGT gene and human renin gene. Our studies suggest that: (a) blood pressure and (b) hAGT mRNA in the liver and kidney is increased in transgenic mice containing -6A haplotype as compared to -6G haplotype. We will now use these transgenic mice to understand the role of glucocorticoids and IL-6 on hAGT gene expression and blood pressure in an in vivo situation. These studies will provide new strategies to reduce blood pressure in hypertensive subjects.
描述(由申请人提供):高血压是心肌梗塞,心力衰竭,血管疾病,中风和肾衰竭的严重危险因素。血管紧张素原(AGT)基因基因座与人类基本高血压有关,其表达通过糖皮质激素和IL-6治疗增加。先前的研究表明,AGT基因的变异-6a与高加索人群和日本人群的血浆AGT水平升高和血压升高有关。然而,与含有-6g等位基因的转基因小鼠相比,含有1.2 kb的启动子的转基因小鼠既没有显示转录升高,也不显示血压升高。我们发现,HAGT基因具有三个SNP(-1670,C/G为-1562和-1561的A/G)和-1670A,-1562C和-1561T的变体几乎总是在变体-6a中发生-1670a,-1562c和-1561T。因此,HAGT基因可以细分为-6a单倍型(包含-6a,-1561T,-1562C,-1670A)或-6g单倍型(包含-6G,-1561G,-15652,-15652,-1670G)。我们的瞬时转染测定法表明,与肝脏和肾细胞中-6g单倍型相比,具有-6a单倍型的报告构建体具有四倍的增加糖皮质激素,而五倍增加了IL -6诱导的启动子活性。为了了解糖皮质激素和IL-6对hagt基因的-6a和-6g单倍型的转录以及在体内情况下血压调节的作用,我们重新召集了180 kb的BAC DNA(包含5'-五范围的5'-五范围内的5'- flank and exons and of 4' - 和54 k的5'- kb bac dna(含有116 kb)基因)并产生了含有-6a或-6g单倍型的双转基因小鼠和人类肾素基因。我们的研究表明:(a)与-6g单倍型相比,在含有-6a单倍型的转基因小鼠中,肝脏和肾脏中的HAGT mRNA增加。现在,我们将使用这些转基因小鼠了解糖皮质激素和IL-6在体内情况下对HAGT基因表达和血压的作用。这些研究将为降低高血压受试者的血压提供新的策略。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

ASHOK KUMAR其他文献

ASHOK KUMAR的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('ASHOK KUMAR', 18)}}的其他基金

TWEAK/Fn14/UPR Signaling in Skeletal Muscle Wasting
骨骼肌萎缩中的 TWEAK/Fn14/UPR 信号转导
  • 批准号:
    10660397
  • 财政年份:
    2023
  • 资助金额:
    $ 35.65万
  • 项目类别:
TAK1 signaling in skeletal muscle
骨骼肌中的 TAK1 信号传导
  • 批准号:
    10201515
  • 财政年份:
    2019
  • 资助金额:
    $ 35.65万
  • 项目类别:
TAK1 signaling in skeletal muscle
骨骼肌中的 TAK1 信号传导
  • 批准号:
    10005646
  • 财政年份:
    2019
  • 资助金额:
    $ 35.65万
  • 项目类别:
Non-Coding Variants of Angiotensinogen Gene and Hypertension
血管紧张素原基因的非编码变异与高血压
  • 批准号:
    9197334
  • 财政年份:
    2016
  • 资助金额:
    $ 35.65万
  • 项目类别:
Non-Coding Variants of Angiotensinogen Gene and Hypertension
血管紧张素原基因的非编码变异与高血压
  • 批准号:
    9325162
  • 财政年份:
    2016
  • 资助金额:
    $ 35.65万
  • 项目类别:
MYD88 Signaling in Mammalian Myoblast Fusion
哺乳动物成肌细胞融合中的 MYD88 信号转导
  • 批准号:
    9144184
  • 财政年份:
    2015
  • 资助金额:
    $ 35.65万
  • 项目类别:
MYD88 Signaling in Mammalian Myoblast Fusion
哺乳动物成肌细胞融合中的 MYD88 信号转导
  • 批准号:
    9336240
  • 财政年份:
    2015
  • 资助金额:
    $ 35.65万
  • 项目类别:
Aldosterone Synthase & Hypertension
醛固酮合酶
  • 批准号:
    9052214
  • 财政年份:
    2014
  • 资助金额:
    $ 35.65万
  • 项目类别:
Aldosterone Synthase and Hypertension
醛固酮合酶与高血压
  • 批准号:
    8673375
  • 财政年份:
    2014
  • 资助金额:
    $ 35.65万
  • 项目类别:
Aldosterone Synthase & Hypertension
醛固酮合酶
  • 批准号:
    8837685
  • 财政年份:
    2014
  • 资助金额:
    $ 35.65万
  • 项目类别:

相似海外基金

The role of transcription factor MEOX2 in lipofibroblast function during alveolarization
转录因子 MEOX2 在肺泡化过程中脂肪成纤维细胞功能中的作用
  • 批准号:
    10385997
  • 财政年份:
    2022
  • 资助金额:
    $ 35.65万
  • 项目类别:
Characterization of TRPC6 to predict and prevent chemotherapy-related heart failure
TRPC6 的表征可预测和预防化疗相关心力衰竭
  • 批准号:
    10705329
  • 财政年份:
    2022
  • 资助金额:
    $ 35.65万
  • 项目类别:
Humanized MAPT knockin mouse models for frontotemporal dementia
额颞叶痴呆人源化 MAPT 敲入小鼠模型
  • 批准号:
    10303887
  • 财政年份:
    2021
  • 资助金额:
    $ 35.65万
  • 项目类别:
Genetics of Hypertension
高血压的遗传学
  • 批准号:
    8302314
  • 财政年份:
    2011
  • 资助金额:
    $ 35.65万
  • 项目类别:
Mechanism of Renal Cell Injury
肾细胞损伤机制
  • 批准号:
    8398924
  • 财政年份:
    2011
  • 资助金额:
    $ 35.65万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了